Repligen | RGEN - Current Assets


Repligen reported $1.16B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agilent USD 4.76B 148M Mar/2026
Align Technology USD 2.66B 38.87M Mar/2026
Bio Techne USD 688.05M 50.62M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Bruker USD 2.1B 108.9M Mar/2026
Charles River Laboratories USD 1.49B 41.76M Mar/2026
Danaher USD 13.94B 1.18B Mar/2026
Dentsply International USD 1.85B 178M Mar/2026
General Electric Aerospace USD 40.36B 235M Mar/2026
Henry Schein USD 4.5B 32M Mar/2026
Illumina USD 2.74B 551M Mar/2026
IQVIA Holdings USD 6.22B 29M Mar/2026
Mettler Toledo International USD 1.33B 30.76M Mar/2026
Myriad Genetics USD 312.8M 19.8M Mar/2026
OraSure Technologies USD 240.78M 21.13M Mar/2026
Pacific Biosciences Of California USD 369.52M 5.54M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Repligen USD 1.16B 23.98M Mar/2026
Revvity USD 2.13B 111.43M Mar/2026
Standard Biotools USD 521.45M 67.19M Mar/2026
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Waters USD 3.72B 1.73B Mar/2026
West Pharmaceutical Services USD 1.83B 151.4M Mar/2026